Reuters logo
Zealand Pharma, Eli Lilly sign obesity, diabetes research deal
August 29, 2013 / 12:06 PM / 4 years ago

Zealand Pharma, Eli Lilly sign obesity, diabetes research deal

COPENHAGEN, Aug 29 (Reuters) - Danish pharmaceutical group Zealand Pharma said it had entered into a research and development agreement with U.S. drugmaker Eli Lilly and Co , with a focus on type two diabetes and obesity.

The companies will join efforts to design and develop potentially novel therapeutic peptides for type two diabetes and obesity, it said in a statement.

The collaboration could also be expanded into other disease areas, Zealand said.

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below